GW Henssler & Associates’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $244K | Hold |
4,662
| – | – | 0.01% | 211 |
|
|
2026
Q1 | $257K | Hold |
4,662
| – | – | 0.01% | 186 |
|
|
2025
Q4 | $229K | Sell |
4,662
-108
| -2% | -$5.04K | 0.01% | 203 |
|
|
2025
Q3 | $206K | Buy |
+4,770
| New | +$186K | 0.01% | 218 |
|
|
2025
Q1 | – | Sell |
-16,407
| Closed | -$671K | – | 197 |
|
|
2024
Q4 | $671K | Sell |
16,407
-2,442
| -13% | -$87.9K | 0.04% | 105 |
|
|
2024
Q3 | $771K | Sell |
18,849
-753,725
| -98% | -$30.8M | 0.04% | 100 |
|
|
2024
Q2 | $29.7M | Sell |
772,574
-21,008
| -3% | -$884K | 1.79% | 16 |
|
|
2024
Q1 | $34M | Sell |
793,582
-9,859
| -1% | -$407K | 2% | 8 |
|
|
2023
Q4 | $29.8M | Sell |
803,441
-13,590
| -2% | -$488K | 1.97% | 10 |
|
|
2023
Q3 | $29.6M | Sell |
817,031
-11,065
| -1% | -$393K | 2.02% | 9 |
|
|
2023
Q2 | $29.5M | Buy |
828,096
+495,581
| +149% | +$17.8M | 1.94% | 9 |
|
|
2023
Q1 | $11.8M | Buy |
332,515
+193,849
| +140% | +$6.78M | 0.79% | 52 |
|
|
2022
Q4 | $4.87M | Buy |
+138,666
| New | +$4.62M | 0.34% | 67 |
|
|
2017
Q4 | – | Sell |
-168,274
| Closed | -$8.54M | – | 146 |
|
|
2017
Q3 | $8.54M | Buy |
168,274
+6,445
| +4% | +$327K | 0.86% | 52 |
|
|
2017
Q2 | $8.72M | Buy |
161,829
+10,955
| +7% | +$584K | 0.91% | 51 |
|
|
2017
Q1 | $7.95M | Buy |
150,874
+25,645
| +20% | +$1.3M | 0.86% | 52 |
|
|
2016
Q4 | $6.03M | Sell |
125,229
-5,889
| -4% | -$291K | 0.67% | 58 |
|
|
2016
Q3 | $7.07M | Buy |
131,118
+3,412
| +3% | +$187K | 0.81% | 54 |
|
|
2016
Q2 | $6.92M | Buy |
127,706
+16,620
| +15% | +$876K | 0.8% | 55 |
|
|
2016
Q1 | $5.63M | Buy |
111,086
+18,291
| +20% | +$911K | 0.66% | 61 |
|
|
2015
Q4 | $4.68M | Sell |
92,795
-19,374
| -17% | -$988K | 0.55% | 65 |
|
|
2015
Q3 | $5.39M | Buy |
112,169
+6,036
| +6% | +$314K | 0.62% | 66 |
|
|
2015
Q2 | $5.53M | Buy |
106,133
+16,817
| +19% | +$947K | 0.6% | 67 |
|
|
2015
Q1 | $5.15M | Buy |
89,316
+10,648
| +14% | +$610K | 0.6% | 47 |
|
|
2014
Q4 | $4.2M | Buy |
78,668
+1,464
| +2% | +$81.9K | 0.47% | 68 |
|
|
2014
Q3 | $4.44M | Buy |
77,204
+4,977
| +7% | +$305K | 0.54% | 59 |
|
|
2014
Q2 | $4.83M | Buy |
72,227
+6,376
| +10% | +$432K | 0.59% | 54 |
|
|
2014
Q1 | $4.4M | Buy |
65,851
+8,100
| +14% | +$548K | 0.52% | 57 |
|
|
2013
Q4 | $3.85M | Buy |
57,751
+3,781
| +7% | +$245K | 0.45% | 55 |
|
|
2013
Q3 | $3.38M | Buy |
53,970
+3,696
| +7% | +$238K | 0.44% | 55 |
|
|
2013
Q2 | $3.14M | Buy |
+50,274
| New | +$3.19M | 0.43% | 54 |
|
Other funds holding GSK
JEST
GW Henssler & Associates's GSK Position: Q2 2026 in Review
GW Henssler & Associates held its GSK (GSK) position steady in Q2 2026 at 4,662 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #211.
GW Henssler & Associates first reported a position in GSK in Q2 2013 and has held it in 31 quarters since. The position peaked at $34M in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- GW Henssler & Associates held 4,662 shares of GSK worth $244K as of Q2 2026.
- GW Henssler & Associates left its GSK share count unchanged in Q2 2026.
- GSK made up 0.01% of GW Henssler & Associates's portfolio in Q2 2026, its #211 holding.
- GW Henssler & Associates first reported a position in GSK in Q2 2013 and has held it in 31 quarters since.
- GW Henssler & Associates's GSK position peaked at $34M in Q1 2024.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on GW Henssler & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.